Congress isn’t done with AbbVie
Nearly two years after opening an investigation into AbbVie’s drug pricing practices, a congressional committee is planning to subpoena the company for internal documents, claiming the drug maker has been less than cooperative in the process.
As STAT’s Ed Silverman reports, the move by the House Committee on Oversight and Reform singles out AbbVie among a dozen drug companies under investigation. Since January 2019, the company’s responses to Congress have been “inconsistent with the expected record-keeping and decision-making processes of a large multinational corporation,” Rep. Carolyn Maloney (D-NY), wrote in a memo.
The inquiry focuses on two AbbVie’s best-selling medicines: Humira, a blockbuster treatment for rheumatoid arthritis, and Imbruvica, a drug for lymphoma. In a statement, AbbVie said the company was “surprised and disappointed” by the threat of subpoena but would “continue to work in good faith” with the House committee.
Read more.
As STAT’s Ed Silverman reports, the move by the House Committee on Oversight and Reform singles out AbbVie among a dozen drug companies under investigation. Since January 2019, the company’s responses to Congress have been “inconsistent with the expected record-keeping and decision-making processes of a large multinational corporation,” Rep. Carolyn Maloney (D-NY), wrote in a memo.
The inquiry focuses on two AbbVie’s best-selling medicines: Humira, a blockbuster treatment for rheumatoid arthritis, and Imbruvica, a drug for lymphoma. In a statement, AbbVie said the company was “surprised and disappointed” by the threat of subpoena but would “continue to work in good faith” with the House committee.
Read more.
.png)
No hay comentarios:
Publicar un comentario